RT Journal Article
T1 Variation in Colonoscopy Performance Measures According to Procedure Indication.
A1 Mangas-Sanjuan, Carolina
A1 Santana, Enrique
A1 Cubiella, Joaquín
A1 Rodríguez-Camacho, Elena
A1 Seoane, Agustín
A1 Alvarez-Gonzalez, Marco Antonio
A1 Suárez, Adolfo
A1 Álvarez-García, Verónica
A1 González, Natalia
A1 Luè, Alberto
A1 Cid-Gomez, Lucía
A1 Ponce, Marta
A1 Bujanda, Luis
A1 Portillo, Isabel
A1 Pellisé, María
A1 Díez-Redondo, Pilar
A1 Herráiz, Maite
A1 Ono, Akiko
A1 Pizarro, Ángeles
A1 Zapater, Pedro
A1 Jover, Rodrigo
A1 QUALISCOPIA Study Investigators, 
K1 ADR
K1 Colon Cancer
K1 Comparison
K1 FIT
AB Most fulfillment and benchmarking information for colonoscopy quality indicators has been obtained from studies of primary screening colonoscopies. We analyzed differences in the fulfillment of colonoscopy quality indicators based on the indication for endoscopy. We performed an observational, multicenter, cross-sectional study of 14,867 patients who underwent endoscopy procedures for gastrointestinal symptoms (40.3%), a positive result from a fecal immunochemical test (36.0%), postpolypectomy surveillance (15.3%), or primary screening (8.4%), from February 2016 through December 2017 at 14 centers in Spain. We evaluated rates of adequate colon cleansing, cecal intubation, adenoma detection, and colorectal cancer detection, among others. We used findings from primary screening colonoscopies as the reference standard. Fewer than 90% of patients had adequate bowel preparation; 83.1% of patients with gastrointestinal symptoms had adequate bowel preparation (odds ratio [OR] compared with patients with primary screening colonoscopies, 0.62; 95% CI, 0.49-0.78) and 85.3% of patients receiving postpolypectomy surveillance had adequate bowel preparation (OR, 0.71; 95% CI, 0.55-0.91). The cecal intubation rate was also lower in patients with gastrointestinal symptoms (93.1%) (OR, 0.34; 95% CI, 0.22-0.52). The adenoma detection rate was higher in patients with a positive result from a fecal immunochemical test (46.4%) (OR, 2.01; 95% CI, 1.71-2.35) and in patients undergoing postpolypectomy surveillance (48.2%) (OR, 1.41; 95% CI, 1.20-1.67). The highest proportion of patients with colorectal cancer was in the gastrointestinal symptom group (5.1%) (OR, 5.24; 95% CI, 2.30-11.93) and the lowest was in patients undergoing surveillance (0.8%) (OR, 0.83; 95% CI, 0.32-2.14). Fulfillment of colonoscopy performance measures varies substantially by indication. Policies addressing performance measures beyond colonoscopy screening procedures should be developed. Benchmarking recommendations could be adjusted according to colonoscopy indication.
YR 2019
FD 2019-08-22
LK http://hdl.handle.net/10668/14438
UL http://hdl.handle.net/10668/14438
LA en
DS RISalud
RD Apr 18, 2025